Breaking News

Financial Report: Covance

May 2, 2014

Late-Stage revenues up 8% in the quarter

Covance

1Q Revenues: $666.3 million (+5%)

1Q Earnings: $50.8 million (+6%)

Comments: Late-Stage Development revenues were up 8% to $402 million in the quarter. Central labs and clinical development were up 11% and 6%, respectively, offsetting a decline in market access services. Early Development revenue was up 5% to $218 million, with growth in clinical pharmacology, research products, and nutritional chemistry offsetting the sale of the Seattle genomics lab and declines in toxicology and discovery support. 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important